HMG

HMG, more formally menotropins or human menopausal gonadotropin, is a clinically established fertility biologic containing both FSH and LH activity. It fits into peptide-centered discussions because it is commonly grouped with injectable reproductive hormones, but it is not a single short peptide entity. In this repository it should be handled as a mixed gonadotropin preparation with strong clinical grounding.

Key names include HMG, hMG, menotropins, and brand names such as Menopur. The repository should also note that modern products may differ from older historical preparations in purity, formulation, route, and manufacturing controls.

3. Sequence and structure

Menotropins are not a single discrete sequence-defined peptide. They are a biologic preparation containing follicle-stimulating hormone activity and luteinizing hormone activity, historically purified from the urine of postmenopausal women. As a result, repository structure fields should capture hormone composition and biologic activity units rather than pretend there is one simple fixed peptide sequence.

HMG stimulates ovarian follicular development through FSH activity while providing LH activity that supports steroidogenesis and maturation dynamics. In some male fertility contexts, gonadotropin combinations involving HMG or analogous FSH-containing products are used to support spermatogenesis.

The most evidence-based and regulated use case is controlled ovarian stimulation in assisted reproductive technology. Broader reproductive-endocrine use should always be labeled according to product, protocol, and region.

HMG is administered by injection, with protocols designed around follicular monitoring rather than a simple standard PK target. Clinical use is tightly linked to ultrasound and hormonal follow-up because biologic response matters more than single concentration measurements.

Evidence in assisted reproduction is mature and clinically established. Outcomes depend heavily on patient selection, protocol, co-administered agents, and cycle management, not on HMG alone in isolation.

Major safety concerns include ovarian hyperstimulation syndrome, multiple gestation risk, abdominal symptoms, thromboembolic risk in susceptible settings, injection-site reactions, and protocol-dependent reproductive complications. This is a high-monitoring medication class.

Dosing is protocol-driven, individualized, and adjusted according to ovarian response. The starter entry should avoid presenting one generic dose because cycle type, response, and co-treatment all matter.

The following dosing information has been compiled from community forums, researcher discussions, and gray-market sources. This information has NOT been verified through peer-reviewed scientific studies or clinical trials. It does NOT constitute medical advice, a prescription, or a recommendation for human use.

This data is presented solely for informational and educational purposes to document what is commonly discussed in research communities. Dosing protocols may be inaccurate, dangerous, or based on anecdotal reports with no scientific validation. Individual responses vary significantly, and unregulated compounds carry inherent risks including contamination, mislabeling, and unknown side effects.

Always consult qualified medical professionals before making any health-related decisions. The repository maintainers assume no liability for the use or misuse of this information.

Researcher-Reported Dosing Protocols

Common Dose Range: 75-150 IU per injection

Administration Route: Subcutaneous or intramuscular injection

Frequency: 3x per week

Timing: Consistent injection days are recommended, but no specific time of day is consistently mentioned.

Schedule / Protocol: 12-16 week cycles

Dose Escalation: No specific escalation protocol is commonly discussed. Researchers typically start with a standard dose and monitor response.

Additional Notes: HMG is often used in combination with HCG (Human Chorionic Gonadotropin) to stimulate spermatogenesis. The dosage can vary depending on the individual's response and the specific research protocol.

This researcher-reported dosing information was compiled from unverified community sources and does not represent validated scientific or medical guidance.

HMG and related gonadotropin protocols have an extensive clinical-trial history in infertility treatment. The modern literature is often comparative, asking when menotropins, recombinant FSH, or combined protocols are preferred.

Approved fertility products exist in major regulated markets. This entry should be tagged as established reproductive biologic therapy, not as speculative peptide use.

13. References and source quality

Best sources include current DailyMed labeling for Menopur or related products, PubChem compound summaries for menotropins, and reproductive-medicine guidelines that contextualize ovarian stimulation protocols and safety. These sources are far more trustworthy than forum-level fertility summaries.

Manufacturing and repository fields should capture product source, FSH/LH activity per vial, diluent, reconstitution method, route, and storage. Because this is a mixed biologic preparation, potency and formulation details matter more than short-sequence peptide conventions.

Closest comparisons are recombinant FSH products, HCG / choriogonadotropin alfa, LH activity products, and broader ART stimulation regimens. Relative to HCG, HMG is the mixed gonadotropin stimulation product rather than the ovulation-trigger hormone.

Version 0.1 starter entry created March 14, 2026. Evidence basis for this draft: DailyMed Menopur labeling, PubChem records, and standard assisted-reproduction practice context.